Feature | February 06, 2014| Dave Fornell

Sapien Aortic Valve Used to Replace Mitral Valve

Henry Ford Hospital in Detroit uses an Edwards Sapien device to replace a mitral valve

Edwards Lifesciences Sapien Transcatheter Aortic Valve Heart Repair Structural
There have been big advances in transcatheter aortic valve replacement (TAVR) technology in recent years and now two such valves on the U.S. market, but there has been little progress toward a transcatheter mitral valve. The U.S. Food and Drug Administration (FDA) cleared the Mitraclip mitral valve leaflet repair system last fall, but for patients requiring a full valve replacement, there is no FDA cleared option. Due to the complexity of the mitral valve anatomy, development of transcatheter treatments for mitral regurgitation has been lacking in comparison to transcatheter aortic valve devices.
 
This did not stop cardiologists at Henry Ford Hospital in Detroit, who recently used an Edwards Lifesciences Sapien TAVR device to replace a mitral valve that was narrowed with calcium buildup. William O'Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, estimates this new technique could help thousands of patients a year in the United States.
 
"The success of this innovative procedure, developed by my team member Dr. Mayra Guerrero, brings new options to physicians for mitral valve repair," O'Neill said in a statement. "Not only did our team implant a different replacement valve than would normally be used in this part of the heart, but we needed to develop a new technique to do it. We were able to implant a different valve, as it was the only way to save the patient."
 
An FDA-approved trial is being planned at Henry Ford Hospital to further investigate the use of the Sapien valve in the mitral valve position. 
 
The patient, Lee Young, 72, of Detroit, has diabetes and had two previous open-heart surgeries. With calcific mitral stenosis, the narrowed mitral valve of his heart was causing shortness of breath, but he was not a candidate for a third open-heart surgery, so the heart team devised a procedure using a Sapien valve.
 
The team of specialists modified the route that is usually used for mitral valvuloplasty, a balloon procedure to open narrowed heart valves. The procedure had been attempted on Young, with little success at opening the mitral valve sufficiently. However, the balloon allowed the team to measure the valve annulus to ensure that the new valve would fit before placement.  
 
The route involves threading a catheter from the femoral vein, passing through the right ventricle, into the right atrium and through the septum into the left atrium. The balloon expandable Sapien valve is delivered through the catheter to the mitral valve. A minimally invasive incision allowed a wire to pass through the chest to the mitral valve, providing stability during the placement of the new valve. 
 
Young has been feeling well for the six weeks following his procedure.
 
Similar Sapien procedures to replace the mitral valve have been performed in Europe since 2011.[1] 
 
European Market Clearance for the Mitral Position

The next generation Edwards Lifesciences Sapien XT is already cleared in Europe for TAVR and for use in the mitral valve. In Febrary 2014, the Sapien XT received an additional European market clearance for use in valve-in-valve procedures, where one device can be implanted over on top of another implanted valve, in both the aortic and mitral valve positions. 

In the United States, the Sapien XT valve is not commercially available and is an investigational device being studied as part of the randomized, pivotal PARTNER II Trial. The device is an improved version of Sapien valve.  

Dedicated Mitral Valve

Canadian-based Neovasc has developed the Tiara device, a dedicated mitral valve replacement device using a self-expanding frame with attached bovine pericardial tissue leaflets mounted inside, similar to a Medtronic CoreValve device. It is delivered through the apex of the heart. 

The first-in-human implantation of the Tiara was successfully performed in January at St. Paul’s Hospital in Vancouver. The transapical procedure eliminated mitral regurgitation and significantly improved the patient's heart function without the need for cardiac bypass support or significant paravalvular leak or procedural complications. 

The device showed further promise based on preclinical swine study published in the February 2014 issue of JACC: Cardiovascular Interventions. The valves were successfully implanted in 81 percent of the swine (n=29). Unsuccessful implantation was due to improper positioning (n=3), failure of the valve anchors to properly engage during deployment (n=2), and ventricular fibrillation (n=2). None of the valves migrated or embolized. The animals with successful implantations all remained hemodynamically stable throughout the procedure. The authors noted some atrial fibrillation when the valve was being manipulated, but there were no sustained arrhythmias after implantation. Major paravalvular leak was seen only in animals with a improperly sized valves. 

Another company, CardiAQ Valve Technologies, is also developing a dedicated transcatheter mitral valve.  Its design uses a foreshortening frame designed to address the specific challenges of the mitral anatomy, and includes numerous proximal and distal anchors connected to the frame. Radial expansion of the frame causes the ends of the anchors on both ends to draw closer together.

The CardiAQ access route is transvenous, transseptal and antegrade. The first in human implant took place in 2012 when it was successfully implanted as a compassionate treatment into an 86-year-old male at The Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark.  
 
Reference:
1. D. Himbert, E. Brochet,, C. Radu, et al. “Transseptal Implantation of a Transcatheter Heart Valve in a Mitral Annuloplasty Ring to Treat Mitral Repair Failure.” Circ Cardiovasc Interv. 2011;4:396-398, doi:10.1161/CIRCINTERVENTIONS.111.962332. Published online 
 

 

Related Content

PFO occluder, amplatzer
Feature | Structural Heart Occluders| May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
CardiAQ, Neovasc, lawsuit, TMVR
News | Business| May 24, 2016
Edwards Lifesciences Corp. announced that a federal jury in Boston returned a verdict in favor of CardiAQ in a lawsuit...
Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
Bioventrix, Revivent-TC System, heart failure, first-in-man procedure
News | Heart Failure| May 19, 2016
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based...
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
Overlay Init